SCHEMBL21043301

SCHEMBL21043301

COCCCOc1cc(CC(=O)C(C)C)ccc1C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.43
PPARA Q07869 1/20 0.43
ABCC8 Q09428 2/20 0.39
PTPN1 P18031 1/20 0.39
PTPN6 P29350 1/20 0.39
PTPN11 Q06124 1/20 0.39
NPC1 O15118 1/20 0.39
CYP2C9 P11712 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ACACB O00763 1/20 0.38
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
KDM4E B2RXH2 1/20 0.38
SLC22A1 O15245 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21043314 0.89 MAPT (0.42) CYP2C9NPSR1ACACBLMNAHTT
SCHEMBL21043370 0.84 LTB4R (0.36) PPARGPPARAACACBLMNAHTT
SCHEMBL18459145 0.84 TSHR (0.48) CYP2C9NPSR1CYP3A4
SCHEMBL29840561 0.84 REN (0.47) NPC1NPSR1LMNAHTT
SCHEMBL16930008 0.84 REN (0.47) NPC1NPSR1LMNAHTT
SCHEMBL21043295 0.84 L3MBTL1 (0.46) NPC1RAB9ALMNAKDM4ECYP3A4
SCHEMBL29840555 0.83 KDM4E (0.41) PPARANPC1CYP2C9RAB9ANPSR1
SCHEMBL16930350 0.83 CYP4F2 (0.40) ACACBCYP4F2CYP4A11
SCHEMBL16930147 0.83 KDM4E (0.41) PPARANPC1CYP2C9RAB9ANPSR1
SCHEMBL8284760 0.82 PPARG (0.48) PPARGPPARAPTPN1PTPN6PTPN11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3694856-B1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-10-25 EP disclosed
EP-3694856-B1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO LTD (CN) 2023-10-25 EP disclosed
CN-110066278-B Fused tricyclic compound and application thereof in medicines 广东东阳光药业有限公司 2021-06-08 CN disclosed
US-10966970-B2 Fused tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-06 US disclosed
US-10966970-B2 Fused tricyclic compounds and uses thereof in medicine SUNSHINE LAKE PHARMA CO., LTD. (CN) 2021-04-06 US disclosed
US-20200113879-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2020-04-16 US disclosed
CN-110066278-A Fused tricyclic class compound and its application in drug 广东东阳光药业有限公司 2019-07-30 CN disclosed
WO-2019100735-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10966970-B2 Fused tricyclic compounds and uses thereof in medicine SLC10A1, CYP11B2, CYP11B1 PPARG 352/4885PPARA 436/4885ABCC8 2336/4885
US-20200113879-A1 FUSED TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE SLC10A1, CYP11B2, CYP11B1 PPARG 352/4885PPARA 436/4885ABCC8 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.